by maheshbhuva | Jun 3, 2026 | Analytical Chemistry, Newsletter
🇺🇸 FDA Updates CAVHANZA (nilotinib) approved (June 2, 2026) for Ph+ chronic myeloid leukemia with improved formulation allowing use alongside PPIs/H2 blockers without restrictions. Ensitrelvir (Xocova) approved (May 29, 2026) as the first oral option for COVID-19...
